Angiotensin converting enzyme inhibitors (ACE inhibitors) are medications that slow (inhibit) the activity of the enzyme ACE, which decreases the production of angiotensin II.
The global market for Angiotensin Converting Enzyme Inhibitors was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Angiotensin Converting Enzyme Inhibitors, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Angiotensin Converting Enzyme Inhibitors by region & country, by Type, and by Application.
The Angiotensin Converting Enzyme Inhibitors market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angiotensin Converting Enzyme Inhibitors.
Market Segmentation
By Company
Pfizer
AstraZeneca
Novartis AG
Daiichi Sankyo, Inc
Sanofi
Merck
Abbott
Segment by Type:
Benazepril (Lotensin)
Captopril
Enalapril (Vasotec)
Fosinopril
Lisinopril (Prinivil, Zestril)
Moexipril
Perindopril
Quinapril (Accupril)
Ramipril (Altace)
Trandolapril
Segment by Application
Coronary Artery Disease
Heart Failure
Diabetes
Chronic Kidney Diseases
Heart Attacks
Scleroderma
Migraines
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Angiotensin Converting Enzyme Inhibitors manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Angiotensin Converting Enzyme Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Angiotensin Converting Enzyme Inhibitors in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Angiotensin Converting Enzyme Inhibitors Product Introduction
1.2 Global Angiotensin Converting Enzyme Inhibitors Market Size Forecast
1.3 Angiotensin Converting Enzyme Inhibitors Market Trends & Drivers
1.3.1 Angiotensin Converting Enzyme Inhibitors Industry Trends
1.3.2 Angiotensin Converting Enzyme Inhibitors Market Drivers & Opportunity
1.3.3 Angiotensin Converting Enzyme Inhibitors Market Challenges
1.3.4 Angiotensin Converting Enzyme Inhibitors Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Angiotensin Converting Enzyme Inhibitors Players Revenue Ranking (2023)
2.2 Global Angiotensin Converting Enzyme Inhibitors Revenue by Company (2019-2024)
2.3 Key Companies Angiotensin Converting Enzyme Inhibitors Manufacturing Base Distribution and Headquarters
2.4 Key Companies Angiotensin Converting Enzyme Inhibitors Product Offered
2.5 Key Companies Time to Begin Mass Production of Angiotensin Converting Enzyme Inhibitors
2.6 Angiotensin Converting Enzyme Inhibitors Market Competitive Analysis
2.6.1 Angiotensin Converting Enzyme Inhibitors Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Angiotensin Converting Enzyme Inhibitors Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angiotensin Converting Enzyme Inhibitors as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Benazepril (Lotensin)
3.1.2 Captopril
3.1.3 Enalapril (Vasotec)
3.1.4 Fosinopril
3.1.5 Lisinopril (Prinivil, Zestril)
3.1.6 Moexipril
3.1.7 Perindopril
3.1.8 Quinapril (Accupril)
3.1.9 Ramipril (Altace)
3.1.10 Trandolapril
3.2 Global Angiotensin Converting Enzyme Inhibitors Sales Value by Type
3.2.1 Global Angiotensin Converting Enzyme Inhibitors Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Angiotensin Converting Enzyme Inhibitors Sales Value, by Type (2019-2030)
3.2.3 Global Angiotensin Converting Enzyme Inhibitors Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Coronary Artery Disease
4.1.2 Heart Failure
4.1.3 Diabetes
4.1.4 Chronic Kidney Diseases
4.1.5 Heart Attacks
4.1.6 Scleroderma
4.1.7 Migraines
4.1.8 Others
4.2 Global Angiotensin Converting Enzyme Inhibitors Sales Value by Application
4.2.1 Global Angiotensin Converting Enzyme Inhibitors Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Angiotensin Converting Enzyme Inhibitors Sales Value, by Application (2019-2030)
4.2.3 Global Angiotensin Converting Enzyme Inhibitors Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Angiotensin Converting Enzyme Inhibitors Sales Value by Region
5.1.1 Global Angiotensin Converting Enzyme Inhibitors Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Angiotensin Converting Enzyme Inhibitors Sales Value by Region (2019-2024)
5.1.3 Global Angiotensin Converting Enzyme Inhibitors Sales Value by Region (2025-2030)
5.1.4 Global Angiotensin Converting Enzyme Inhibitors Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Angiotensin Converting Enzyme Inhibitors Sales Value, 2019-2030
5.2.2 North America Angiotensin Converting Enzyme Inhibitors Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Angiotensin Converting Enzyme Inhibitors Sales Value, 2019-2030
5.3.2 Europe Angiotensin Converting Enzyme Inhibitors Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Angiotensin Converting Enzyme Inhibitors Sales Value, 2019-2030
5.4.2 Asia Pacific Angiotensin Converting Enzyme Inhibitors Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Angiotensin Converting Enzyme Inhibitors Sales Value, 2019-2030
5.5.2 South America Angiotensin Converting Enzyme Inhibitors Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Angiotensin Converting Enzyme Inhibitors Sales Value, 2019-2030
5.6.2 Middle East & Africa Angiotensin Converting Enzyme Inhibitors Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Angiotensin Converting Enzyme Inhibitors Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Angiotensin Converting Enzyme Inhibitors Sales Value
6.3 United States
6.3.1 United States Angiotensin Converting Enzyme Inhibitors Sales Value, 2019-2030
6.3.2 United States Angiotensin Converting Enzyme Inhibitors Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Angiotensin Converting Enzyme Inhibitors Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Angiotensin Converting Enzyme Inhibitors Sales Value, 2019-2030
6.4.2 Europe Angiotensin Converting Enzyme Inhibitors Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Angiotensin Converting Enzyme Inhibitors Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Angiotensin Converting Enzyme Inhibitors Sales Value, 2019-2030
6.5.2 China Angiotensin Converting Enzyme Inhibitors Sales Value by Type (%), 2023 VS 2030
6.5.3 China Angiotensin Converting Enzyme Inhibitors Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Angiotensin Converting Enzyme Inhibitors Sales Value, 2019-2030
6.6.2 Japan Angiotensin Converting Enzyme Inhibitors Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Angiotensin Converting Enzyme Inhibitors Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Angiotensin Converting Enzyme Inhibitors Sales Value, 2019-2030
6.7.2 South Korea Angiotensin Converting Enzyme Inhibitors Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Angiotensin Converting Enzyme Inhibitors Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Angiotensin Converting Enzyme Inhibitors Sales Value, 2019-2030
6.8.2 Southeast Asia Angiotensin Converting Enzyme Inhibitors Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Angiotensin Converting Enzyme Inhibitors Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Angiotensin Converting Enzyme Inhibitors Sales Value, 2019-2030
6.9.2 India Angiotensin Converting Enzyme Inhibitors Sales Value by Type (%), 2023 VS 2030
6.9.3 India Angiotensin Converting Enzyme Inhibitors Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Profile
7.1.2 Pfizer Main Business
7.1.3 Pfizer Angiotensin Converting Enzyme Inhibitors Products, Services and Solutions
7.1.4 Pfizer Angiotensin Converting Enzyme Inhibitors Revenue (US$ Million) & (2019-2024)
7.1.5 Pfizer Recent Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Profile
7.2.2 AstraZeneca Main Business
7.2.3 AstraZeneca Angiotensin Converting Enzyme Inhibitors Products, Services and Solutions
7.2.4 AstraZeneca Angiotensin Converting Enzyme Inhibitors Revenue (US$ Million) & (2019-2024)
7.2.5 AstraZeneca Recent Developments
7.3 Novartis AG
7.3.1 Novartis AG Profile
7.3.2 Novartis AG Main Business
7.3.3 Novartis AG Angiotensin Converting Enzyme Inhibitors Products, Services and Solutions
7.3.4 Novartis AG Angiotensin Converting Enzyme Inhibitors Revenue (US$ Million) & (2019-2024)
7.3.5 Daiichi Sankyo, Inc Recent Developments
7.4 Daiichi Sankyo, Inc
7.4.1 Daiichi Sankyo, Inc Profile
7.4.2 Daiichi Sankyo, Inc Main Business
7.4.3 Daiichi Sankyo, Inc Angiotensin Converting Enzyme Inhibitors Products, Services and Solutions
7.4.4 Daiichi Sankyo, Inc Angiotensin Converting Enzyme Inhibitors Revenue (US$ Million) & (2019-2024)
7.4.5 Daiichi Sankyo, Inc Recent Developments
7.5 Sanofi
7.5.1 Sanofi Profile
7.5.2 Sanofi Main Business
7.5.3 Sanofi Angiotensin Converting Enzyme Inhibitors Products, Services and Solutions
7.5.4 Sanofi Angiotensin Converting Enzyme Inhibitors Revenue (US$ Million) & (2019-2024)
7.5.5 Sanofi Recent Developments
7.6 Merck
7.6.1 Merck Profile
7.6.2 Merck Main Business
7.6.3 Merck Angiotensin Converting Enzyme Inhibitors Products, Services and Solutions
7.6.4 Merck Angiotensin Converting Enzyme Inhibitors Revenue (US$ Million) & (2019-2024)
7.6.5 Merck Recent Developments
7.7 Abbott
7.7.1 Abbott Profile
7.7.2 Abbott Main Business
7.7.3 Abbott Angiotensin Converting Enzyme Inhibitors Products, Services and Solutions
7.7.4 Abbott Angiotensin Converting Enzyme Inhibitors Revenue (US$ Million) & (2019-2024)
7.7.5 Abbott Recent Developments
8 Industry Chain Analysis
8.1 Angiotensin Converting Enzyme Inhibitors Industrial Chain
8.2 Angiotensin Converting Enzyme Inhibitors Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Angiotensin Converting Enzyme Inhibitors Sales Model
8.5.2 Sales Channel
8.5.3 Angiotensin Converting Enzyme Inhibitors Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Pfizer
AstraZeneca
Novartis AG
Daiichi Sankyo, Inc
Sanofi
Merck
Abbott
听
听
*If Applicable.
